Zoekresultaten - 24 results

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.

Y Debie; M Huizing; Pieter Pannus; K Neven; K K Ariën; G. A. Martens; Marc Van den Bulcke; E Roelant; I Desombere; S Anguille; Maria Goossens; T Vandamme; P van Dam Source: ESMO Open, Volume 6, Issue ...

Performance of five rapid serological tests in mild-diseased subjects using finger prick blood for exposure assessment to SARS-CoV-2.

Robben; Pieter Pannus; Kristof Neven; Dirk Ramaekers; Steven Van Gucht; Katelijne Dierick; Nele Van Loon; Maria Goossens; I Desombere Source: J Clin Virol, Volume 142 (2021) Keywords: Antibodies, Viral ...

Monitoring of the immune response to SARS-CoV-2 in vulnerable populations: the COVICO study (2023-2026)

Verbrugghe; Isabelle Maufort; Léo Hendrickx; Pieter Pannus; Véronique Olislagers; Kevien Ariën; Arnaud Marchant; I Desombere; Maria Goossens Source: Scientific Seminar ‘Diagnosis and surveillance of infectious ...

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial (poster)

Publication Type: Scientific poster, presentation or proceeding Authors: Pannus, Pieter; Depickère, Stéphanie; Kemlin, Delphine; Houben, Sarah; Neven, Christophe Y.; Hendrickx, Leo; Michiels, Johan; ...

QR code

QR code for this page URL